Whalesbook
Ab dekho, company ne khud announce kiya hai ki unhe Argentina ke national regulatory authority se unke antibiotic, Ceftriaxone, ke liye marketing authorization mil gayi hai.
Yeh approval Venus Remedies ke liye Latin America mein ek super important step hai, jisse unka global product portfolio aur bhi mazboot hoga. Sach toh ye hai ki Ceftriaxone ab tak 39 countries mein marketing approval paa chuka hai.
Company ka kehna hai ki isse 'vital anti-infective treatments' tak access improve hoga, aur ye India ko quality injectable medicines ka global supplier banane mein bhi help karega. Saransh Chaudhary, jo Global Critical Care ke president hain, unhone bola ki ye approval "region mein hamari presence ko strong karne ka ek important step hai."
Ab thoda market ki baat karte hain. Argentina, Latin America ka chautha sabse bada pharma market hai, jiski value 2023 mein lagbhag $7.3 billion thi. Ceftriaxone ek aisa antibiotic hai jo meningitis, respiratory tract infections, aur surgical infections jaise serious bacterial infections ko theek karne mein bahut kaam aata hai, isliye hospitals mein iski demand rehti hai. Company ki strategy ke hisaab se ye clinically important aur accessible anti-infective drugs worldwide offer karne mein bilkul fit baithta hai.
Aur haan, poore Latin America pharma market ki baat karein toh, ye 2024 mein estimated $91.85 billion se badhkar 2034 tak $172.71 billion hone ka target hai. Aditi K Chaudhary, jo International Business ki president hain, ne is approval ko "Latin America expansion journey mein ek strategically important milestone" bataya hai. Agar India ke export figures dekhein toh, 2024 mein India ne Argentina ko lagbhag $17.5 million ke pharma products export kiye hain. Aur dekho, Latin America aur Caribbean region toh India ke total pharma exports ka 6.69% raha FY25 mein. Toh bada potential hai bhai!